Taub Rebecca 4

Accession 0001628280-26-001961

CIK 0001157601other

View on SEC.gov Company Profile

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 4:34 PM ET

Size

53.2 KB

Accession

0001628280-26-001961

Insider Transaction Report

Form 4

Period: 2026-01-09

MADRIGAL PHARMACEUTICALS, INC.MDGL

Taub Rebecca

Director

Transactions

Exercise/Conversion
Common Stock
2026-01-09$15.80/sh+18,410$290,878→ 473,999 total
Sale
Common Stock
[F1][F2]
2026-01-09$512.02/sh−960$491,537→ 473,039 total
Sale
Common Stock
[F1][F3]
2026-01-09$513.12/sh−960$492,595→ 472,079 total
Sale
Common Stock
[F1][F4]
2026-01-09$514.63/sh−937$482,207→ 471,142 total
Sale
Common Stock
[F1][F5]
2026-01-09$515.82/sh−1,578$813,968→ 469,564 total
Sale
Common Stock
[F1][F6]
2026-01-09$516.81/sh−521$269,257→ 469,043 total
Sale
Common Stock
[F1][F7]
2026-01-09$517.84/sh−2,044$1,058,468→ 466,999 total
Sale
Common Stock
[F1][F8]
2026-01-09$518.67/sh−970$503,106→ 466,029 total
Sale
Common Stock
[F1][F9]
2026-01-09$519.89/sh−539$280,220→ 465,490 total
Sale
Common Stock
[F1][F10]
2026-01-09$521.11/sh−440$229,289→ 465,050 total
Sale
Common Stock
[F1][F11]
2026-01-09$521.95/sh−588$306,909→ 464,462 total
Sale
Common Stock
[F1][F12]
2026-01-09$522.98/sh−732$382,823→ 463,730 total
Sale
Common Stock
[F1][F13]
2026-01-09$524.06/sh−1,335$699,623→ 462,395 total
Sale
Common Stock
[F1][F14]
2026-01-09$525.12/sh−1,489$781,903→ 460,906 total
Sale
Common Stock
[F1][F15]
2026-01-09$526.05/sh−913$480,281→ 459,993 total
Sale
Common Stock
[F1][F16]
2026-01-09$526.95/sh−1,135$598,091→ 458,858 total
Sale
Common Stock
[F1][F17]
2026-01-09$528.16/sh−465$245,593→ 458,393 total
Sale
Common Stock
[F1][F18]
2026-01-09$529.28/sh−554$293,222→ 457,839 total
Sale
Common Stock
[F1][F19]
2026-01-09$530.45/sh−256$135,796→ 457,583 total
Sale
Common Stock
[F1]
2026-01-09$531.05/sh−30$15,931→ 457,553 total
Sale
Common Stock
[F1]
2026-01-09$532.50/sh−40$21,300→ 457,513 total
Sale
Common Stock
[F1][F20]
2026-01-09$534.18/sh−271$144,761→ 457,242 total
Sale
Common Stock
[F1][F21]
2026-01-09$534.93/sh−89$47,609→ 457,153 total
Sale
Common Stock
[F1][F22]
2026-01-09$535.80/sh−299$160,205→ 456,854 total
Sale
Common Stock
[F1][F23]
2026-01-09$536.88/sh−385$206,700→ 456,469 total
Sale
Common Stock
[F1]
2026-01-09$537.84/sh−40$21,514→ 456,429 total
Sale
Common Stock
[F1][F24]
2026-01-09$539.26/sh−400$215,706→ 456,029 total
Sale
Common Stock
[F1]
2026-01-09$540.26/sh−40$21,610→ 455,989 total
Sale
Common Stock
[F1]
2026-01-09$542.72/sh−400$217,088→ 455,589 total
Exercise/Conversion
Stock Option (Right to Buy)
[F26]
2026-01-09−18,410→ 240 total
Exercise: $15.80Exp: 2027-03-02→ Common Stock (18,410 underlying)

Holdings

Common Stock
[F25]
(indirect: By LLC)
655,540

Footnotes (26)

[F1]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
[F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.46 to $521.45, inclusive.
[F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.50 to $522.49, inclusive.
[F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.51 to $523.47, inclusive.
[F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.59 to $524.58, inclusive.
[F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.59 to $525.56, inclusive.
[F15]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.59 to $526.55, inclusive.
[F16]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.63 to $527.58, inclusive.
[F17]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.71 to $528.52, inclusive.
[F18]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.72 to $529.69, inclusive.
[F19]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.97 to $530.63, inclusive.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.71 to $512.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
[F20]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.60 to $534.57, inclusive.
[F21]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.60 to $534.99, inclusive.
[F22]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.62 to $536.32, inclusive.
[F23]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.30, inclusive.
[F24]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.00 to $539.44, inclusive.
[F25]The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
[F26]The shares underlying this stock option are fully vested and exercisable.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.00 to $513.58, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.32 to $515.25, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.32 to $516.29, inclusive.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.32 to $517.26, inclusive.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.36 to $518.35, inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.39 to $519.29, inclusive.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.45 to $520.38, inclusive.

Signature

/s/ Mardi Dier, as Attorney-in-Fact|2026-01-13

Documents

1 file

4
wk-form4_1768340044.xmlPrimary
FORM 4

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

→

Entity typeother

Related Parties

filerCIK 0001423898

Filing Metadata

Form type: 4
Filed: Jan 12, 7:00 PM ET
Accepted: Jan 13, 4:34 PM ET
Size: 53.2 KB

View on SEC.gov